AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Trends and Disparities in Hypertensive Disease Mortality Among Adults with Gastroesophageal Reflux Disease, United States, 1999-2024: A Multiple Cause of Death Analysis
By Rizvi SVZ, Arshad MU, Rizvi SUA et al.
Background: Hypertension is a leading cause of cardiovascular morbidity and mortality. Gastroesophageal reflux disease (GERD) affects roughly one in five U.S. adults and shares cardiometabolic risk factors, including obesity and metabolic syndrome, with hypertension. Its symptoms overlap with angina and frequently prompt cardiac evaluation. Proton pump inhibitors, the mainstay of GERD therapy, interact with antiplatelet agents and have been associated with cardiovascular risk. Despite these intersections, national mortality trends in adults with both conditions are not well described.Hypothesis: We hypothesized that mortality from coexisting GERD and hypertensive disease rose from 1999 to 2024, paralleling increases in obesity and GERD prevalence, and varied across demographic and geographic subgroups. Methods: We analyzed the CDC WONDER Multiple Cause of Death database from 1999 to 2024. We identified adults 25 years and older with both GERD and hypertensive disease by ICD-10 codes listed on the death certificate. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated using the 2000 U.S. standard population. We used Joinpoint regression to estimate average annual percent changes (AAPCs) with 95% confidence intervals (CIs) for subgroups with stable annual counts. Trends were examined by sex, age, race, census region, urbanization, place of death, and state.Results: We identified 105,399 deaths. The overall AAMR (per 100,000) rose more than 8-fold, from 0.30 (95% CI, 0.27-0.32) in 1999 to 2.59 (95% CI, 2.53-2.65) in 2024 (AAPC 8.25%; 95% CI, 7.38-9.26). Rates increased in both males (AAPC 8.40%; 95% CI, 7.53-9.63) and females (6.57%; 5.72-7.93). The increase was larger in White (AAPC 8.73%; 95% CI, 7.89-9.66) than Black adults (7.04%; 5.98-8.55). Among adults aged 55 and older, rates rose in every group and most steeply at 55-64 years (AAPC 9.36%; 95% CI, 8.07-11.59). By region, the Northeast had the largest increase (8.82%; 6.16-11.99), followed by the South (8.26%; 7.39-9.56). Rates also rose in both metropolitan (9.51%; 8.52-10.74) and non-metropolitan (10.51%; 9.00-12.32) areas through 2020. All AAPCs were significant (p<0.001).Conclusion: Mortality involving co-listed GERD and hypertensive disease rose substantially from 1999 to 2024, with the largest increases among males, White adults, and adults aged 55-64 years. These widening demographic and geographic disparities support targeted cardiovascular risk reduction in adults with coexisting GERD and hypertension.